Short Note on Bioinformation Techniques in Cancer Treatment

Parisa Zarkeshian[*]

Department of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India

DESCRIPTION

According to the World Health Organization, cancer is one of the leading causes of death in the world, with approximately 10 million deaths in 2020. Cancers that kill the most people in the world include breast cancer, lung cancer, stomach cancer, colon cancer, and rectal cancer. There are various risk factors that can lead to cancer, from the type of diet to the type of viral infection. However, the annual number of deaths from cancer can be reduced by early detection of cancer. If appropriate treatment is provided, the chances of the cancer being cured are very high. The development of microarray technology has made it possible to obtain large amounts of data on genes that are differentially expressed from cancer cells. Therefore, this vast amount of data uses computational tools and databases to store, process, and extract valuable information from the collected data, for example to discover new biomarkers for cancer diagnosis. Therefore, this requires the application of bioinformatics resources to perform this task. This study focused to improve the diagnosis of cancer using a variety of bioinformatics tools.

The bioinformatics tools and databases can be used to detect different diagnostic biomarkers associated with different types of cancer, including cervical cancer, ovarian cancer, pancreatic cancer, and lung cancer. Therefore, the detected biomarkers help improve early detection of cancer and thus reduce cancer-related mortality. The study also showed that some of the biomarkers identified for one type of cancer are common to other types of cancer. Therefore, bioinformatics plays an important role in improving the diagnosis of cancer by recognizing biomarkers that can be used to diagnose cancer. Bioinformatics also helps identify genes that are differentially expressed from common biomarkers in different types of cancer, further improving the process of cancer diagnosis. The series also demonstrates the potential to integrate large and diverse datasets and use machine learning approaches to develop multivariable predictors with significantly improved clinical outcomes. For example, an artificial intelligence-based deep learning approach is highly effective in using noise reduction auto encoders to curate the clinical and outcome-related deep learning features of breast cancer and integrate genomic data from multiple sources. In addition, artificial intelligence-based classification techniques have also been used in several independent colorectal cancer datasets to identify and validate diagnostic and prognostic biomarkers that may have a significant impact on the disease. As another example, the accuracy of analyzing cancer registry databases to assess the 90-day risk of curative surgery-related mortality and overall survival in patients with locally advanced head and neck cancer. The value of the Wu comorbidity score was determined. We will use a machine learning-based decision support system to extract data from electronic medical records and demonstrate the usefulness of improving prognostic variables. Another approach, and understanding how the generator set correlates with the results. A self-organizing mapping approach was used to curate publicly available cancer data and derivative gene signatures associated with the three biological subtypes of the disease. A new dataset has also been generated to compare the molecular composition of primary colorectal cancer and brain metastases.

CONCLUSION

In an interesting computational approach, analysis of published data on steroid hormone-related gene sets identified steroid-producing acute regulatory proteins as potential prognostic biomarkers for breast cancer. Similarly, a meta-analysis of the gene expression omnibus and cancer genome atlas miRNA datasets prioritized candidate biomarkers for oral cancer prognosis and overall survival. Machine learning approaches are also used to prioritize related miRNAs and validate the performance of top miRNAs in classification models, and prioritizing targets from expression data is very effective. It suggests that it is a strategy. Analysis of miRNA data using the observed survival intervals has been reported to overcome the problem of relevance of clinical outcomes. Together, suggest the possibilities of these approaches in this new era of machine learning approaches. Finally, additional analysis of similar datasets also plays a role in detailed characterization of clinical features in avoiding analytical bias in biological and clinical outcomes when analyzing large datasets.

Correspondence to: Parisa Zarkeshian, Department of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India, Tel/Fax: +44 (0)300 019 6175; E-mail: parisazarkeshian@gmail.com